Neuropeptide y receptor Y2 gene polymorphism interacts with plasma neuropeptide y levels in predicting left ventricular hypertrophy in dialysis patients

Journal of Hypertension

Volumn 28, Issue 8, 2010, Pages 1745-1751

  Testa, Alessandra ^a   Mallamaci, Francesca ^a   MacRì, Roberta ^a   Pisano, Anna ^a   Spoto, Belinda ^a   Malatino, Lorenzo S ^c   Stancanelli, Benedetta ^c   Tripepi, Giovanni ^a   Benedetto, Francesco A ^b   Zoccali, Carmine ^a  

^a NATIONAL RESEARCH COUNCIL   (United States)

^b Morelli Hospital   (Italy)

^c UNIVERSITY OF CATANIA   (Italy)

Author keywords

cardiovascular risk; end stage kidney disease; genetics; neuropeptide Y; neuropeptide Y receptor

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NEUROPEPTIDE Y; NEUROPEPTIDE Y2 RECEPTOR;

ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR RISK; CONTROLLED STUDY; DNA POLYMORPHISM; ECHOCARDIOGRAPHY; FEMALE; GENE FREQUENCY; GENE INTERACTION; GENETIC VARIABILITY; HEART LEFT VENTRICLE HYPERTROPHY; HEMODIALYSIS PATIENT; HUMAN; HYPERTENSION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL;

EID: 77954954844     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32833bd21b     Document Type: Article

References (40)

1. Zoccali C. Neuropeptide Y as a far-reaching neuromediator: from energy balance and cardiovascular regulation to central integration of weight and bone mass control mechanisms. Implications for human diseases. Curr Opin Nephrol Hypertens 2005; 14:25-32.
2. Wheway J, Mackay CR, Newton RA, Sainsbury A, Boey D, Herzog H, et al. A fundamental bimodal role for neuropeptide Y1 receptor in the immune system. J Exp Med 2005; 202:1527-1538.
3. De Mey JG, Megens R, Fazzi GE. Functional antagonism between endogenous neuropeptide Y and calcitonin gene-related peptide in mesenteric resistance arteries. J Pharmacol Exp Ther 2008; 324:930-937.
4. Zukowska-Grojec Z, Pruszczyk P, Colton C, Yao J, Shen GH, Myers AK, et al. Mitogenic effect of neuropeptide Y in rat vascular smooth muscle cells. Peptides 1993; 14:263-268.
5. Li L, Lee EW, Ji H, Zukowska Z. Neuropeptide Y-induced acceleration of postangioplasty occlusion of rat carotid artery. Arterioscler Thromb Vasc Biol 2003; 23:1204-1210.
6. Nicholl SM, Bell D, Spiers J, McDermott BJ. Neuropeptide Y Y(1) receptor regulates protein turnover and constitutive gene expression in hypertrophying cardiomyocytes. Eur J Pharmacol 2002; 441:23-34.
7. Lee EW, Grant DS, Movafagh S, Zukowska Z. Impaired angiogenesis in neuropeptide Y (NPY)-Y2 receptor knockout mice. Peptides 2003; 24:99-106.
8. Millar BC, Schluter KD, Zhou XJ, McDermott BJ, Piper HM. Neuropeptide Y stimulates hypertrophy of adult ventricular cardiomyocytes. Am J Physiol Cell Physiol 1994; 266:C1271-C1277.
9. Ullman B, Hulting J, Lundberg JM. Prognostic value of plasma neuropeptide-Y in coronary care unit patients with and without acute myocardial infarction. Eur Heart J 1994; 15:454-461.
10. Feng QP, Hedner T, Andersson B, Lundberg JM, Waagstein F. Cardiac neuropeptide Y and noradrenaline balance in patients with congestive heart failure. Br Heart J 1994; 71:261-267.
11. Callanan EY, Lee EW, Tilan JU, Winaver J, Haramati A, Mulroney SE, et al. Renal and cardiac neuropeptide Y and NPY receptors in a rat model of congestive heart failure. Am J Physiol Renal Physiol 2007; 293:F1811-F1817.
12. Bald M, Gerigk M, Rascher W. Elevated plasma concentrations of neuropeptide Y in children and adults with chronic and terminal renal failure. Am J Kidney Dis 1997; 30:23-27.
13. Klin M, Waluga M, Rudka R, Madej A, Janiszewska M, Grzebieniak E, et al. Plasma catecholamines, neuropeptide Y and leucine-enkephalin in uremic patients before and after dialysis during rest and handgrip. Boll Chim Farm 1998; 137:306-313.
14. Zoccali C, Mallamaci F, Tripepi G, Benedetto FA, Parlongo S, Cutrupi S, et al. Neuropeptide Y, left ventricular mass and function in patients with end stage renal disease. J Hypertens 2003; 21:1355-1362.
15. Zoccali C, Mallamaci F, Tripepi G, Benedetto FA, Parlongo S, Cutrupi S, et al. Prospective study of neuropeptide Y as an adverse cardiovascular risk factor in end-stage renal disease. J Am Soc Nephrol 2003; 14:2611-2617. (Pubitemid 37169347)
16. Jager KJ, Zoccali C, Macleod A, Dekker FW. Confounding: what it is and how to deal with it. Kidney Int 2008; 73:256-260.
17. Zoccali C, Testa A, Spoto B, Tripepi G, Mallamaci F. Mendelian randomization: a new approach to studying epidemiology in ESRD. Am J Kidney Dis 2006; 47:332-341.
18. Santoro N,Del Giudice EM, Grandone A,MarzuilloP, Cozzolino D, DiSalvo G, et al. Y2 receptor gene variants reduce the risk of hypertension in obese children and adolescents. J Hypertens 2008; 26:1590-1594.
19. Shah SH, Freedman NJ, Zhang L, Crosslin DR, Stone DH, Haynes C, et al. Neuropeptide Y gene polymorphisms confer risk of early-onset atherosclerosis. PLoS Genet 2009; 5:e1000318.
20. Arnett DK, Devereux RB, Rao DC, Li N, Tang W, Kraemer R, et al. Novel genetic variants contributing to left ventricular hypertrophy: the HyperGEN study. J Hypertens 2009; 27:1585-1593.
21. Foley RN, Parfrey PS, Harnett JD, Kent GM, Martin CJ, Murray DC, et al. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int 1995; 47:186-192.
22. London GM, Pannier B, Guerin AP, Blacher J, Marchais SJ, Darne B, et al. Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: follow-up of an interventional study. J Am Soc Nephrol 2001; 12:2759-2767.
23. Zoccali C, Bode-Boger S, Mallamaci F, Benedetto F, Tripepi G, Malatino L, et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 2001; 358:2113-2117.
24. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16:1215.
25. De Simone G, Daniels SR, Devereux RB, Meyer RA, Roman MJ, De Divitiis O, Alderman MH. Left ventricular mass and body size in normotensive children and adults: assessment of allometric relations and impact of overweight. J Am Coll Cardiol 1992; 20:1251-1260.
26. Zoccali C, Benedetto FA, Mallamaci F, Tripepi G, Giacone G, Cataliotti A, et al. Prognostic impact of the indexation of left ventricular mass in patients undergoing dialysis. J Am Soc Nephrol 2001; 12:2768-2774.
27. Zoccali C, Mallamaci F, Tripepi G, Benedetto FA, Cottini E, Giacone G, et al. Prediction of left ventricular geometry by clinic, predialysis and 24-h ambulatory BP monitoring in hemodialysis patients: CREED investigators. J Hypertens 1999; 17:1751-1758.
28. Altman DG. Practical statistics for medical research, 1st edn. London: Chapman and Hall; 1991.
29. Penne EL, Neumann J, Klein IH, Oey PL, Bots ML, Blankestijn PJ. Sympathetic hyperactivity and clinical outcome in chronic kidney disease patients during standard treatment. J Nephrol 2009; 22:208-215.
30. Zoccali C, Mallamaci F, Tripepi G, Parlongo S, Cutrupi S, Benedetto FA, et al. Norepinephrine and concentric hypertrophy in patients with end-stage renal disease. Hypertension 2002; 40:41-46.
31. Zoccali C, Mallamaci F, Parlongo S, Cutrupi S, Benedetto FA, Tripepi G, et al. Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation 2002; 105:1354-1359. (Pubitemid 34260428)
32. Kuch-Wocial A, Slubowska K, Kostrubiec M, Pasierski T, Januszewicz W, Switalska H, et al. Plasma neuropeptide Y immunoreactivity influences left ventricular mass in pheochromocytoma. Clin Chim Acta 2004; 345:43-47.
33. Chen M, Li X, Dong Q, Li Y, Liang W. Neuropeptide Y induces cardiomyocyte hypertrophy via calcineurin signaling in rats. Regul Pept 2005; 125:9-15.
34. Simpson P. Norepinephrine-stimulated hypertrophy of cultured rat myo-cardial cells is an 1 adrenergic response. J Clin Invest 1983; 72:732-738.
35. Davey Smith G, Ebrahim S. 'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol 2003; 32:1-22.
36. Abe K, Tilan JU, Zukowska Z. NPY and NPY receptors in vascular remodeling. Curr Top Med Chem 2007; 7:1704-1709.
37. Coelho EF, Ferrari MFR, Maximino JR, Fior-Chadi DR. Change in the expression of NPY receptors subtypes Y1 and Y2 in central and peripheral neurons related to the control of blood pressure in rats following experimental hypertension. Neuropeptides 2004; 38:77-82.
38. Aguirre JA, Hedlund PB, Narvá ez JA, Bunnemann B, Ganten D, Fuxe K. Increased vasopressor actions of intraventricular neuropeptide Y-(13-36) in spontaneously hypertensive versus normotensive Wistar-Kyoto rats. Possible relationship to increases in Y2 receptor binding in the nucleus tractus solitarius. Brain Res 1995; 684:159-164.
39. Ekstrand AJ, Cao R, Bjorndahl M, Nystrom S, Jonsson-Rylander AC, Hassani H, et al. Deletion of neuropeptide Y (NPY) 2 receptor in mice results in blockage of NPY-induced angiogenesis and delayed wound healing. Proc Natl Acad Sci USA 2003; 100:6033-6038.
40. Zukowska-Grojec Z, Karwatowska-Prokopczuk E, Rose W, Rone J, Movafagh S, Ji H, et al. Neuropeptide Y: a novel angiogenic factor from the sympathetic nerves and endothelium. Circ Res 1998; 83:187-195.